Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) announced its earnings results on Friday. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05), Zacks reports.
Monogram Orthopaedics Stock Performance
Shares of MGRM traded down $0.02 during trading hours on Thursday, hitting $5.46. The company had a trading volume of 214,892 shares, compared to its average volume of 413,267. The firm has a fifty day moving average price of $4.40 and a 200-day moving average price of $3.26. The stock has a market capitalization of $194.86 million, a price-to-earnings ratio of -10.92 and a beta of 0.69. Monogram Orthopaedics has a 52-week low of $1.92 and a 52-week high of $6.02.
Hedge Funds Weigh In On Monogram Orthopaedics
A hedge fund recently raised its stake in Monogram Orthopaedics stock. Jane Street Group LLC grew its holdings in shares of Monogram Orthopaedics Inc. (NASDAQ:MGRM - Free Report) by 83.0% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,426 shares of the company's stock after purchasing an additional 8,810 shares during the quarter. Jane Street Group LLC owned approximately 0.06% of Monogram Orthopaedics worth $57,000 as of its most recent filing with the Securities & Exchange Commission. 0.45% of the stock is owned by hedge funds and other institutional investors.
About Monogram Orthopaedics
(
Get Free Report)
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Featured Stories
Before you consider Monogram Orthopaedics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monogram Orthopaedics wasn't on the list.
While Monogram Orthopaedics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access